In this article, we consider the new drugs approved for the European market in 
2015. We present a summary of the new mechanisms of action introduced and 
highlight three new mechanisms of action with a potentially high future impact: 
PCSK9 inhibition (alirocumab (Praluent®) and evolocumab (Repatha®)) for 
hypercholesterolaemia, neprilysin inhibition (sacubitril in combination with 
valsartan (Entresto®)) for heart failure, and interleukin-5 inhibition 
(mepolizumab (Nucala®)) for asthma.